ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / LTGO / earnings
SVRA (35) MLTX (36) JANX (41) RIGL (75) ⌘ Pro Terminal →

Latigo Biotherapeutics Inc. (LTGO) Next Earnings Date & Expected ±12.5% Move

$13.95 -10.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.67

Latigo Biotherapeutics Inc. (LTGO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • SELL / AVOID Cap $1.03B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LTGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $13.95 (-10.23% 1D, market cap $1.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LTGO ranks #456 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LTGO compare to SVRA and MLTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SVRA (Savara Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LTGO?
▼

Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.67 (-2.03%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (5)SEC (13)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$27 Bull$13 Base$10 Bear
📬 FREE LTGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTGO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY LTGO SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0.7% FCF Margin ($28.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$16.02-10.7% Next Q
Q2 (-2Q)
48
Grade D$14.30+6.7% Next Q
Q3 (-1Q)
46
Grade D$15.26-8.6% Next Q
Current
43
Grade D-$13.95-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LTGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LTGO currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.78) and Max Pain ($14.65) forces dealer call-delta covering toward $27.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LTGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LTGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.74 Expected Swing
$12.21 (-12.5%)Spot $13.95$15.69 (+12.5%)
MODEL EARNINGS SETUP GAUGE

LTGO Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (43/100)Model Risk Weight (57/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0$0$052%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTGO)

  • ✓Walkthrough of LTGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LTGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.56%▼ DESCENDING CHANNEL
2026-11-02O $15.83H $15.83L $13.95C $13.95VOL 141.7K
RES: $22.46SUP: $11.02SMA50: $18.78SMA200: $18.97
$26.80$23.20$19.59$15.99$12.38RES $22.46SUP $11.02$13.952026-08-072026-08-282026-09-212026-10-122026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LTGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LTGO Butterfly Map → + Track LTGO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LTGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LTGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LTGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTGO)

Health Care Rank #456 of 1016 ⚔️ SVRA vs LTGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LTGO vs. SVRA, MLTX, JANX, RIGL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Latigo Biotherapeutics Inc. (LTGO) ranks #456 by composite RQD confidence (43/100, grade D-) and #358 by equity capitalization ($1.03B). Within this direct 5-issuer industry benchmark cohort, LTGO leads on earnings valuation at N/A trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with LTGO at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LTGO ACTIVE
Latigo Biotherapeutics Inc.
D- 43/100 — — — -10.23% $1.03B Benchmark Subject
SVRA
Savara Inc.
D- 35/100 — — -35.0% -2.63% $1.02B /svra-vs-ltgo →
MLTX
MoonLake Immunotherapeutics (Class A)
D- 36/100 — — -35.0% -6.28% $1.07B /mltx-vs-ltgo →
JANX
Janux Therapeutics Inc.
D- 41/100 — — -13.8% -2.02% $1.09B /janx-vs-ltgo →
RIGL
Rigel Pharmaceuticals Inc.
B 75/100 — 93.3% 28.2% -0.27% $961.1M /rigl-vs-ltgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002056611

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Latigo Biotherapeutics Inc. (LTGO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LTGO closed FY2025 with $75.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 $0 — — $75.5M —

3. LTGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $13.95 (-10.23% 1D, market cap $1.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LTGO ranks #456 in composite RQD confidence.

How does LTGO compare to SVRA and MLTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SVRA (Savara Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LTGO?

Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LTGO trading relative to its 50-day, 200-day, and 52-week technical levels?

LTGO last traded at $13.95 (-10.23% on volume of 216,180 shares), positioning the stock -25.72% below its 50-day simple moving average ($18.78) and -26.46% below its 200-day simple moving average ($18.97). Across its 52-week range of $13.50 to $25.93, LTGO sits at the 3.6% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.21 to $15.69).

LTGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is LTGO's next earnings date?

Based on SEC filing cadence, Latigo Biotherapeutics Inc. (LTGO)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is LTGO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for LTGO, spanning a range between $12.21 and $15.69.

Direct Sub-Reports: LTGO RQD Cockpit LTGO 12M Forecast LTGO Earnings & Move LTGO Dividends & DRIP LTGO Insiders & 13F LTGO Whale Options LTGO Profit Sankey LTGO News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LTGO — Latigo Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:16Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LTGO scores 43 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

  • Fundamental Cash Engine (10 / 20): Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash-flow yield to support the current valuation from operations.
  • Whale 13F Flow (5 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the lowest-scoring pillar, indicating weak institutional support in the source data. Holder-level detail is not available in source data.
  • Insider Conviction (9 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score indicates limited insider-conviction signal.
  • Macro Regime Fit (6 / 20): Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 implies market-level sensitivity; the low score reflects weak fit with the current regime as measured by the rating model.
  • Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the highest-scoring pillar and represents the relative strength of the company's balance sheet in the source data.

Investor implications: The composite score is driven by zero reported ROIC and FCF yield, weak institutional flow, and limited insider conviction, partially offset by a comparatively stronger balance-sheet profile. A prospective investor evaluating the stock today would need to weigh a valuation with no operating-cash-return support against a balance sheet the rating model rates as moderately sound.

Business

Latigo Biotherapeutics Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the company profile, the issuer has a market capitalization of $1.0B. Specific products, customers, and revenue model details are not available in source data. Per the SEC financials, reported revenue for FY 2025 is $0.0M.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$0.0M$0.0M$0.0MN/AN/A$69.4MN/A

Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with gross, operating, and net margins each at 0% per the market data. Per the Roarable RQD rating, ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. Reported cash is $69.4M per the SEC financials; debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference LTGO, all flagged with a YELLOW light and MARKET WIRE impact label. Headlines reference the company's stock price and news coverage, a NaV1.8 market commentary piece suggesting the company "May Be The One To Profit From It," an estimates report, a report of the stock hitting a new 12-month low, and a report of shares rising 5.5%. Per the market data, the stock is down 1.83% on the session, and the 52-week range runs from $13.5 to $25.93. The feed contains no specific clinical, regulatory, or commercial catalyst details beyond these headlines. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Risk watch: The new 12-month low headline, sitting alongside a price near the bottom of the 52-week range, is the most directly relevant risk item in the feed.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is recorded as NONE, with no upstream or downstream links and no proprietary signals. Upstream/downstream dependencies, sector correlations beyond the stated sector and industry, and second-order bottlenecks are not available in source data.

Open Questions

  • What are the company's specific pipeline assets and development milestones, given the source data lists no revenue and no operating income?
  • What is the nature of the reported $69.4M cash position relative to the cash burn implied by zero revenue and zero operating income?
  • What is the debt balance, since debt is listed as N/A despite a reported Debt/Equity of 0.5?
  • What is the basis for the "NaV1.8 market" commentary and does it reflect any specific program or partnership?
  • Who holds the shares, given that holder data is not available in source data?

LTGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Latigo Biotherapeutics Inc. (LTGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LTGO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LTGO Bull vs. Bear Conversation Board — What's Your Call at $13.95?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LTGO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on LTGO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $13.68 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LTGO (D- • RQD 43/100) a Buy at $15.54?

Welcome to the LTGO (Latigo Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.12 (-22.0%)
Spot @ $15.54

Pump the brakes on LTGO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LTGO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Latigo Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $17.87 (+15.0%)
Spot @ $15.54

LTGO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LTGO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.54 (52-wk range $13.50 - $25.93), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%